DRI HEALTHCARE TRUST (DHT-UN.CA) Stock Price, Forecast & Analysis
Canada - Toronto Stock Exchange - TSX:DHT-UN - CA23344H1091
16 CAD
-0.15 (-0.93%)
We assign a fundamental rating of 4 out of 10 to DHT-UN. DHT-UN was compared to 33 industry peers in the Pharmaceuticals industry. DHT-UN may be in some trouble as it scores bad on both profitability and health. DHT-UN scores decently on growth, while it is valued quite cheap. This could make an interesting combination.
1. Profitability
1.1 Basic Checks
In the past year DHT-UN was profitable.
In the past year DHT-UN had a positive cash flow from operations.
1.2 Ratios
The Return On Assets of DHT-UN (-5.75%) is comparable to the rest of the industry.
With a Return On Equity value of -11.95%, DHT-UN perfoms like the industry average, outperforming 53.13% of the companies in the same industry.
DHT-UN has a Return On Invested Capital of 4.55%. This is in the better half of the industry: DHT-UN outperforms 71.88% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for DHT-UN is significantly below the industry average of 8.14%.
The last Return On Invested Capital (4.55%) for DHT-UN is above the 3 year average (1.94%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.75% | ||
| ROE | -11.95% | ||
| ROIC | 4.55% |
ROA(3y)4.16%
ROA(5y)N/A
ROE(3y)6.27%
ROE(5y)N/A
ROIC(3y)1.94%
ROIC(5y)N/A
1.3 Margins
DHT-UN's Operating Margin of 27.25% is amongst the best of the industry. DHT-UN outperforms 93.75% of its industry peers.
In the last couple of years the Operating Margin of DHT-UN has declined.
DHT-UN does not have Profit Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.25% | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3Y-6.12%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), DHT-UN is destroying value.
Compared to 1 year ago, DHT-UN has about the same amount of shares outstanding.
Compared to 1 year ago, DHT-UN has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.38, we must say that DHT-UN is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of DHT-UN (1.38) is better than 75.00% of its industry peers.
The Debt to FCF ratio of DHT-UN is 4.45, which is a neutral value as it means it would take DHT-UN, 4.45 years of fcf income to pay off all of its debts.
DHT-UN has a better Debt to FCF ratio (4.45) than 75.00% of its industry peers.
DHT-UN has a Debt/Equity ratio of 0.90. This is a neutral value indicating DHT-UN is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.90, DHT-UN is doing worse than 78.13% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.9 | ||
| Debt/FCF | 4.45 | ||
| Altman-Z | 1.38 |
ROIC/WACC0.56
WACC8.12%
2.3 Liquidity
DHT-UN has a Current Ratio of 1.14. This is a normal value and indicates that DHT-UN is financially healthy and should not expect problems in meeting its short term obligations.
DHT-UN's Current ratio of 1.14 is on the low side compared to the rest of the industry. DHT-UN is outperformed by 78.13% of its industry peers.
A Quick Ratio of 1.14 indicates that DHT-UN should not have too much problems paying its short term obligations.
DHT-UN has a Quick ratio (1.14) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.14 |
3. Growth
3.1 Past
DHT-UN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.41%.
DHT-UN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 5.09% yearly.
DHT-UN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.24%.
Measured over the past years, DHT-UN shows a very strong growth in Revenue. The Revenue has been growing by 32.25% on average per year.
EPS 1Y (TTM)-7.41%
EPS 3Y5.09%
EPS 5YN/A
EPS Q2Q%22.22%
Revenue 1Y (TTM)16.24%
Revenue growth 3Y32.25%
Revenue growth 5YN/A
Sales Q2Q%7%
3.2 Future
Based on estimates for the next years, DHT-UN will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.76% on average per year.
DHT-UN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.26% yearly.
EPS Next Y-4.49%
EPS Next 2Y3.01%
EPS Next 3Y9.29%
EPS Next 5Y17.76%
Revenue Next Year11.21%
Revenue Next 2Y6.15%
Revenue Next 3Y6.13%
Revenue Next 5Y15.26%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 7.11, which indicates a rather cheap valuation of DHT-UN.
Compared to the rest of the industry, the Price/Earnings ratio of DHT-UN indicates a rather cheap valuation: DHT-UN is cheaper than 87.50% of the companies listed in the same industry.
DHT-UN is valuated cheaply when we compare the Price/Earnings ratio to 26.57, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 6.95, the valuation of DHT-UN can be described as very cheap.
87.50% of the companies in the same industry are more expensive than DHT-UN, based on the Price/Forward Earnings ratio.
DHT-UN is valuated cheaply when we compare the Price/Forward Earnings ratio to 24.04, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.11 | ||
| Fwd PE | 6.95 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of DHT-UN indicates a somewhat cheap valuation: DHT-UN is cheaper than 75.00% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of DHT-UN indicates a rather cheap valuation: DHT-UN is cheaper than 81.25% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.71 | ||
| EV/EBITDA | 8.39 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.01%
EPS Next 3Y9.29%
5. Dividend
5.1 Amount
DHT-UN has a Yearly Dividend Yield of 4.57%, which is a nice return.
Compared to an average industry Dividend Yield of 0.34, DHT-UN pays a better dividend. On top of this DHT-UN pays more dividend than 100.00% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.00, DHT-UN pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.57% |
5.2 History
DHT-UN has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y3.01%
EPS Next 3Y9.29%
TSX:DHT-UN (12/24/2025, 7:00:00 PM)
16
-0.15 (-0.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners51.1%
Inst Owner ChangeN/A
Ins Owners0.93%
Ins Owner ChangeN/A
Market Cap881.76M
Revenue(TTM)192.69M
Net Income(TTM)-52.23M
Analysts80
Price Target22.08 (38%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.57% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.74%
Min EPS beat(2)-4.46%
Max EPS beat(2)0.99%
EPS beat(4)2
Avg EPS beat(4)3.59%
Min EPS beat(4)-21.52%
Max EPS beat(4)39.35%
EPS beat(8)5
Avg EPS beat(8)18.58%
EPS beat(12)6
Avg EPS beat(12)10.35%
EPS beat(16)8
Avg EPS beat(16)65.99%
Revenue beat(2)1
Avg Revenue beat(2)3.28%
Min Revenue beat(2)-0.37%
Max Revenue beat(2)6.93%
Revenue beat(4)2
Avg Revenue beat(4)13.03%
Min Revenue beat(4)-0.64%
Max Revenue beat(4)46.19%
Revenue beat(8)5
Avg Revenue beat(8)25.66%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.58%
PT rev (3m)12.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.56%
EPS NY rev (1m)-0.58%
EPS NY rev (3m)3.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.84%
Revenue NY rev (1m)0.46%
Revenue NY rev (3m)0.58%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.11 | ||
| Fwd PE | 6.95 | ||
| P/S | 4.58 | ||
| P/FCF | 8.71 | ||
| P/OCF | 8.62 | ||
| P/B | 2.02 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.39 |
EPS(TTM)2.25
EY14.06%
EPS(NY)2.3
Fwd EY14.39%
FCF(TTM)1.84
FCFY11.48%
OCF(TTM)1.86
OCFY11.6%
SpS3.5
BVpS7.93
TBVpS-5.79
PEG (NY)N/A
PEG (5Y)N/A
Graham Number20.04
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.75% | ||
| ROE | -11.95% | ||
| ROCE | 6.33% | ||
| ROIC | 4.55% | ||
| ROICexc | 4.76% | ||
| ROICexgc | 98.84% | ||
| OM | 27.25% | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | 52.55% |
ROA(3y)4.16%
ROA(5y)N/A
ROE(3y)6.27%
ROE(5y)N/A
ROIC(3y)1.94%
ROIC(5y)N/A
ROICexc(3y)2.05%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.74%
ROCE(5y)N/A
ROICexgc growth 3Y44.9%
ROICexgc growth 5YN/A
ROICexc growth 3Y-7.25%
ROICexc growth 5YN/A
OM growth 3Y-6.12%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.21
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.9 | ||
| Debt/FCF | 4.45 | ||
| Debt/EBITDA | 2.53 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 66.17% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.14 | ||
| Altman-Z | 1.38 |
F-Score4
WACC8.12%
ROIC/WACC0.56
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.41%
EPS 3Y5.09%
EPS 5YN/A
EPS Q2Q%22.22%
EPS Next Y-4.49%
EPS Next 2Y3.01%
EPS Next 3Y9.29%
EPS Next 5Y17.76%
Revenue 1Y (TTM)16.24%
Revenue growth 3Y32.25%
Revenue growth 5YN/A
Sales Q2Q%7%
Revenue Next Year11.21%
Revenue Next 2Y6.15%
Revenue Next 3Y6.13%
Revenue Next 5Y15.26%
EBIT growth 1Y343.32%
EBIT growth 3Y24.15%
EBIT growth 5YN/A
EBIT Next Year107.92%
EBIT Next 3Y27.94%
EBIT Next 5Y29.01%
FCF growth 1Y103.46%
FCF growth 3Y19.16%
FCF growth 5YN/A
OCF growth 1Y103.46%
OCF growth 3Y19.16%
OCF growth 5YN/A
DRI HEALTHCARE TRUST / DHT-UN.CA FAQ
What does DRI HEALTHCARE TRUST do?
DRI Healthcare Trust is an unincorporated open-ended company. The company is headquartered in Toronto, Ontario and currently employs 36 full-time employees. The company went IPO on 2021-02-11. The firm provides capital to universities and research institutions, academic institutions, biotechnology companies and pharmaceutical companies. The company has acquired more than 75 royalties on 45-plus drugs, including Ekterly, Eylea, Keytruda, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. Its portfolio includes Empaveli/Syfovre, Eylea I, Eylea II, Natpara, Omidria, Oracea, Orserdu I, Orserdu II, Rydapt, Vonjo I, Vonjo II, Xenpozyme, Xolair, Zejula, and other products. Its therapeutic areas include oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, lysosomal storage disorders (LSD) and immunology. The Company’s products are marketed by pharmaceutical companies, including Regeneron, Bayer, Santen; Vertex Pharmaceuticals; KalVista, Galderma and others.
Can you provide the latest stock price for DRI HEALTHCARE TRUST?
The current stock price of DHT-UN.CA is 16 CAD. The price decreased by -0.93% in the last trading session.
How is the ChartMill rating for DRI HEALTHCARE TRUST?
DHT-UN.CA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.